2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
147
Carcinoma, Renal Cell
37
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Neoplasms
28
Cholangiocarcinoma
26
Endometrial Neoplasms
19
Thyroid Neoplasms
17
Liver Neoplasms
17
Melanoma
15
Stomach Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Biliary Tract Neoplasms
13
Recurrence
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
8
Ovarian Neoplasms
8
Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Triple Negative Breast Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Small Cell Lung Carcinoma
5
Neuroendocrine Tumors
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Kidney Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Interventions
enzalutamide
7
Abiraterone Acetate
4
abiraterone
3
Prednisone
3
Docetaxel
3
sapanisertib
1
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-Resistant Prostate Cancer
×
lenvatinib
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled